A Phase 3 interventional study of Collagenase Clostridium Histolyticum in Dupuytren's Contracture, sponsored by Asahi Kasei Therapeutics Corporation. Completed at 20 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.
Sponsored by Asahi Kasei Therapeutics Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 6th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 3, and was the 11th registered.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
Browse Dupuytren Contracture studies →None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2012.
This study's enrollment of 104 is above the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Median enrollment 76 across the 17 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Asahi Kasei Therapeutics Corporation is the lead sponsor of 2 studies on the registry; none are open to participants now.
Asahi Kasei Therapeutics Corporation has 1 study filed under Dupuytren Contracture — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture.
To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients meeting any of the following criteria will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Collagenase Clostridium Histolyticum
AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
Also known as: Xiaflex® (US), Xiapex® (EU)
The Percentage of Participants That Were Successfully Treated With a "Successful Reduction in Contracture to 5°or Less"
The Primary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the percentage of 77 participants that were successfully treated where "successfully treated" was defined as reduction in the contracture of the first treated joint to 5° or less. The injection was allowed up to 3 times.
Time frame: 30 days after the last injection
Clinical Improvement After the Last Injection
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the percentage of 77 participants that were clinically improved where "clinically improved" was defined as reduction in the contracture of the first treated joint by 50% or more from the baseline. The injection was allowed up to 3 times.
Time frame: 30 days after the last injection
Percent Reduction From Baseline Contracture After the Last Injection
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the mean percent decrease from baseline degree of contracture in primary joints after the last injection. The injection was allowed up to 3 times.
Time frame: 30 days after last treatment
Change From Baseline Range of Motion After the Last Injection
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the change from baseline range of motion in primary joints after the last injection. The injection was allowed up to 3 times.
Time frame: 30 days after last treatment
Time to First Achieve and Maintain Clinical Success After the Last Injection
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the time to first achieve and maintain clinical success after the last injection where "clinical success" was defined as reduction in the contracture of the first treated joint to 5° or less. The injection was allowed up to 3 times.
Time frame: First evaluation visit on which clinical success is achieved and maintained through the Day 30 evaluation of each injections, assessed up to 3 months
104 patients were enrolled, and 102 received AK160. This study proceeded stepwise from Step1 through Step3. First, 6 patients were enrolled in Step1 at the selected study centers, thereafter, 71 and 25 patients were enrolled in Steps2 and3 respectively at all centers. The primary endpoint was determined in 77 participants enrolled in Steps1 and 2.
| Milestone | AK160 0.58 mg Step1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 |
|---|---|---|---|
| Started | 6 | 0 | 0 |
| Completed | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | AK160 0.58 mg Step1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 |
|---|---|---|---|
| Started | 0 | 71 | 0 |
| Completed | 0 | 70 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Milestone | AK160 0.58 mg Step1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 |
|---|---|---|---|
| Started | 0 | 0 | 25 |
| Completed | 0 | 0 | 23 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 |
The Primary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the percentage of 77 participants that were successfully treated where "successfully treated" was defined as reduction in the contracture of the first treated joint to 5° or less. The injection was allowed up to 3 times.
| % Participants | AK160 0.58 mg Step 1-2 |
|---|---|
| The Percentage of Participants That Were Successfully Treated With a "Successful Reduction in Contracture to 5°or Less" | 86 |
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the percentage of 77 participants that were clinically improved where "clinically improved" was defined as reduction in the contracture of the first treated joint by 50% or more from the baseline. The injection was allowed up to 3 times.
| % Participants | Primary MP Joints | Primary PIP Joints | Total |
|---|---|---|---|
| Clinical Improvement After the Last Injection | 100 (92.5 to 100.0) | 90.0 (73.5 to 97.9) | 96.1 (89.0 to 99.2) |
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the mean percent decrease from baseline degree of contracture in primary joints after the last injection. The injection was allowed up to 3 times.
| % of change from baseline | Primary MP Joints | Primary PIP Joints | Total |
|---|---|---|---|
| Percent Reduction From Baseline Contracture After the Last Injection | 97.08 ± 7.791 | 82.48 ± 24.674 | 91.39 ± 17.900 |
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the change from baseline range of motion in primary joints after the last injection. The injection was allowed up to 3 times.
| Degrees | Primary MP Joints | Primary PIP Joints | Total |
|---|---|---|---|
| Change From Baseline Range of Motion After the Last Injection | 41.6 ± 18.91 | 33.3 ± 17.73 | 38.4 ± 18.79 |
The Secondary Outcome Measure for participants who were enrolled at Step1 through Step2 and treated with AK160 is the time to first achieve and maintain clinical success after the last injection where "clinical success" was defined as reduction in the contracture of the first treated joint to 5° or less. The injection was allowed up to 3 times.
| Days | Primary MP Joints | Primary PIP Joints | Total |
|---|---|---|---|
| Time to First Achieve and Maintain Clinical Success After the Last Injection | 1.0 (1.0 to 28.0) | 7.0 (1.0 to 92.0) | 1.0 (1.0 to 30.0) |
Collected over Adverse events were investigated from the day of the first injection of the study drug until 360 days after the first injection of the study drug.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AK160 0.58 mg Step 1-3 | — | 14/102 (13.7%) | 100/102 (98%) |
| Event | AK160 0.58 mg Step 1-3 |
|---|---|
| CataractEye disorders | 3/102 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 |
| Duodenal ulcer perforationGastrointestinal disorders | 1/102 |
| Intestinal obstructionGastrointestinal disorders | 1/102 |
| Infectious pleural effusionInfections and infestations | 1/102 |
| Bile duct stoneHepatobiliary disorders | 1/102 |
| SpondylolysisMusculoskeletal and connective tissue disorders | 1/102 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/102 |
| Event | AK160 0.58 mg Step 1-3 |
|---|---|
| Injection site painGeneral disorders | 78/102 |
| Injection site bruisingGeneral disorders | 46/102 |
| Injection site swellingGeneral disorders | 35/102 |
| ContusionInjury, poisoning and procedural complications | 30/102 |
| Injection site lacerationGeneral disorders | 16/102 |
| NasopharyngitisInfections and infestations | 16/102 |
| Injection site oedemaGeneral disorders | 12/102 |
| Injection site haematomaGeneral disorders | 11/102 |
| Local swellingGeneral disorders | 9/102 |
| LacerationInjury, poisoning and procedural complications | 9/102 |
| Age, Categorical(Participants) | AK160 0.58 mg Step 1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 22 | 2 | 26 |
| >=65 years | 4 | 49 | 23 | 76 |
| Age, Continuous(years) | AK160 0.58 mg Step 1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 | Total |
|---|---|---|---|---|
| Mean | 69 ± 8.3 | 68 ± 8.4 | 71 ± 5.9 | 68.7 ± 8.0 |
| Sex: Female, Male(Participants) | AK160 0.58 mg Step 1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 | Total |
|---|---|---|---|---|
| Female | 1 | 6 | 3 | 10 |
| Male | 5 | 65 | 22 | 92 |
| Region of Enrollment(participants) | AK160 0.58 mg Step 1 | AK160 0.58 mg Step 2 | AK160 0.58 mg Step3 | Total |
|---|---|---|---|---|
| Japan | 6 | 71 | 25 | 102 |
The record gives a start of May 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase
Asahi Kasei Therapeutics Corporation